Hepatitis C. Chapter I Certain infectious and parasitic diseases,Viral hepatitis (B15-B19)
Conditions
Interventions
Intervention 1: Intervention group: 1.intervention group is cirrhosis patients with hepatitis C that would take 12 weeks of Sofosbovir 400 mg and Daclatasvir 60 mg (Sovodak) 1 pill made by Abidi plus
Sponsors
Rasht University of Medical Sciences
Eligibility
Sex/Gender
All
Age
35 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients who have not been treated before Patients who had been treated before, but their illness recurred Patients who could not take interferon
Exclusion criteria
Exclusion criteria: Patients who did not use the medication completely Patients with severe drug side effects Patients who were reluctant to participate in the plan
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HCV treatment. Timepoint: 12 weeks after the end of treatment. Method of measurement: HCV- RNA PCR. | — |
Secondary
| Measure | Time frame |
|---|---|
| Possible side effect. Timepoint: Weeks 0.2, 4, 8, 12 and response to treatment, 24 weeks after the end of drug use (SVR 24. Method of measurement: weeks 2, 12 and 24 weeks after the end of drug use with use of PCR and 4,8 with use of liver enzymes test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Farahnaz Joukar
Rasht University of Medical Sciences
Outcome results
None listed